Literature DB >> 20221355

Didactic migraine education in US doctor of pharmacy programs.

Richard G Wenzel1, Rosalyn S Padiyara, Jon C Schommer.   

Abstract

OBJECTIVE: To compare didactic migraine education in doctor of pharmacy (PharmD) programs in the United States with the Headache Consortium's evidence-based migraine treatment recommendations.
METHODS: A self-administered survey instrument was mailed to all 90 Accreditation Council for Pharmacy Education (ACPE) approved PharmD programs in the United States.
RESULTS: Seventy-seven programs responded (86%) and 69 useable survey instruments were analyzed. Fifty-five percent of programs discussed the Consortium's guidelines, 49% discussed the selection of nonprescription versus prescription agents, 45% recommended a butalbital-containing product as migraine treatment, and 20% educated students about tools for assessing migraine-related debilitation. At least 50% of programs taught information consistent with the remaining Consortium recommendations.
CONCLUSION: Approximately half of the PharmD programs teach concepts about migraine headache treatment consistent with the US Headache Consortium's recommendations.

Entities:  

Keywords:  evidence-based; headache; migraine; pharmacy education

Mesh:

Year:  2010        PMID: 20221355      PMCID: PMC2829152          DOI: 10.5688/aj740104

Source DB:  PubMed          Journal:  Am J Pharm Educ        ISSN: 0002-9459            Impact factor:   2.047


  37 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

Review 2.  Over-the-counter drugs for acute migraine attacks: literature review and recommendations.

Authors:  Richard G Wenzel; Carrie A Sarvis; Michelle L Krause
Journal:  Pharmacotherapy       Date:  2003-04       Impact factor: 4.705

3.  Migraine in the United States: epidemiology and patterns of health care use.

Authors:  R B Lipton; A I Scher; K Kolodner; J Liberman; T J Steiner; W F Stewart
Journal:  Neurology       Date:  2002-03-26       Impact factor: 9.910

4.  Headache education in colleges of pharmacy.

Authors:  Richard G Wenzel; Mindy R Neidich
Journal:  Ann Pharmacother       Date:  2002-04       Impact factor: 3.154

Review 5.  Pharmacologic management of acute attacks of migraine and prevention of migraine headache.

Authors:  Vincenza Snow; Kevin Weiss; Eric M Wall; Christel Mottur-Pilson
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

6.  Reliability and validity of the migraine therapy assessment questionnaire.

Authors:  Mary Lou Chatterton; Jennifer H Lofland; Aaron Shechter; Walter Scott Curtice; X Henry Hu; Jeffrey Lenow; Stanton N Smullens; David B Nash; Stephen D Silberstein
Journal:  Headache       Date:  2002 Nov-Dec       Impact factor: 5.887

7.  Treatment patterns of isolated benign headache in US emergency departments.

Authors:  David R Vinson
Journal:  Ann Emerg Med       Date:  2002-03       Impact factor: 5.721

Review 8.  Do butalbital-containing products have a role in the management of migraine?

Authors:  Richard G Wenzel; Carrie A Sarvis
Journal:  Pharmacotherapy       Date:  2002-08       Impact factor: 4.705

9.  The acute treatment of episodic and chronic migraine in the USA.

Authors:  M E Bigal; S Borucho; D Serrano; R B Lipton
Journal:  Cephalalgia       Date:  2009-02-13       Impact factor: 6.292

Review 10.  Should butalbital-containing analgesics be banned? Yes.

Authors:  William B Young; Hua Chiang Siow
Journal:  Curr Pain Headache Rep       Date:  2002-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.